WALTHAM, MA - October 20, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced the appointment of Jeff Lemaster as Chief Commercial Officer.
Mr. Lemaster brings 20 years of commercial sales and marketing experience in the cardiovascular medical device industry to Corindus and has extensive global new product launch experience in the areas of interventional cardiology and peripheral. He most recently served as Global Vice President, Marketing of C.R. Bard, Inc. [NYSE: BCR], a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies. He has a proven track record of commercial success having held senior sales and marketing leadership positions at C.R. Bard, ACIST Medical Systems and Boston Scientific Corporation [NYSE: BSX].
As Chief Commercial Officer at Corindus, Mr. Lemaster will lead and execute revenue and commercial strategy to drive growth and market adoption globally.
"I am delighted to welcome Jeff to Corindus, and we look forward to his future contributions. His extensive commercial experience, particularly in the interventional and peripheral arena, will enable us to build and sustain strong robotic programs that benefit our customers and their patients," said Corindus CEO, Mark J. Toland.
"I look forward to working with the Corindus team and the broader interventional community to build robotic programs that transform the way we treat patients while protecting cath lab teams," said Mr. Lemaster.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: